AstraZeneca to buy US-listed Fusion Pharma for $2bn
Fusion Pharmaceuticals Inc
$21.55
11:00 15/07/24
0.00%
$0.00
AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.
AstraZeneca
9,903.00p
17:15 08/11/24
1.83%
178.00p
FTSE 100
8,072.39
17:14 08/11/24
n/a
n/a
FTSE 350
4,459.45
16:59 08/11/24
n/a
n/a
FTSE All-Share
4,417.83
16:44 08/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,418.41
16:59 08/11/24
1.22%
233.86
Fusion specialises in radioconjugates, which combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells.
AstraZeneca will pay $21 a share for Fusion, a premium of more than 97% to the US-listed company's closing price on Monday and a non-transferable contingent value right of $3 per share, taking the combined transaction value to about $2.4bn.
Reporting by Frank Prenesti for Sharecast.com